Intech Investment Management LLC Acquires New Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Intech Investment Management LLC purchased a new stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 24,382 shares of the company’s stock, valued at approximately $439,000.

Several other institutional investors and hedge funds also recently made changes to their positions in TEVA. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $14,840,000. Factorial Partners LLC lifted its holdings in Teva Pharmaceutical Industries by 14.3% in the third quarter. Factorial Partners LLC now owns 311,000 shares of the company’s stock valued at $5,604,000 after buying an additional 39,000 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in Teva Pharmaceutical Industries during the third quarter valued at $455,000. Caprock Group LLC grew its holdings in Teva Pharmaceutical Industries by 9.9% during the 3rd quarter. Caprock Group LLC now owns 145,370 shares of the company’s stock worth $2,620,000 after acquiring an additional 13,068 shares during the period. Finally, Pathstone Holdings LLC raised its position in shares of Teva Pharmaceutical Industries by 6.5% in the 3rd quarter. Pathstone Holdings LLC now owns 72,598 shares of the company’s stock worth $1,308,000 after acquiring an additional 4,452 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on the company. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Barclays raised their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. boosted their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Stock Performance

TEVA stock opened at $16.65 on Tuesday. The business has a 50 day moving average of $17.54 and a 200-day moving average of $17.36. The firm has a market cap of $18.86 billion, a PE ratio of -19.59, a P/E/G ratio of 1.30 and a beta of 0.87. Teva Pharmaceutical Industries Limited has a 12-month low of $9.35 and a 12-month high of $19.31. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57.

Insider Activity

In other news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. This represents a 30.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.